Knight Therapeutics (TSE:GUD) Shares Up 1.4% - Time to Buy?

Knight Therapeutics Inc. (TSE:GUD - Get Free Report)'s stock price traded up 1.4% during mid-day trading on Monday . The stock traded as high as C$5.66 and last traded at C$5.65. 39,592 shares changed hands during mid-day trading, a decline of 31% from the average session volume of 57,472 shares. The stock had previously closed at C$5.57.

Analyst Ratings Changes

Separately, Raymond James raised shares of Knight Therapeutics to a "moderate buy" rating in a report on Friday, November 15th.

Knight Therapeutics Stock Performance

The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52. The company's fifty day moving average price is C$5.47 and its two-hundred day moving average price is C$5.56. The company has a market cap of C$568.46 million, a price-to-earnings ratio of -18.76, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.